Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study

Hollander, Eric; Rossi, Nicolò Baldini; Sood, Erica; Pallanti, Stefano

doi:10.1017/s1461145703003730

Cited by 198Obsessive-Compulsive Spectrum DisordersSchizophrenia research and treatmentPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study

Open access

Hollander, Eric, Rossi, Nicolò Baldini, Sood, Erica, Pallanti, Stefano·2003·The International Journal of Neuropsychopharmacology

DOI 10.1017/s1461145703003730

Open this paper in CoChat — free account Open PDF

Abstract

This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease >/=25%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1017/s1461145703003730

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Second-generation antipsychotic agents have shown benefit in OCD, either alone or as adjunctive therapy; high-dose olanzapine, quetiapine, and risperidone have all shown at least minimal clinical benefit relative to placebo.
“Recently, second-generation antipsychotic agents have shown benefit, either alone or as adjunctive therapy. Specifically, high-dose olanzapine [522], quetiapine [523], and risperidone [524] have all shown at least minimal clinical benefit relative to placebo treatment [525].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [524]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.
Kim, S.-W., Dysken, M., Pheley, A., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,333
A Rating Scale for Depression
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 566
Clinical Predictors of Drug Response in Obsessive-Compulsive Disorder
Erzegovesi, S., Cavallini, M. C., Cavedini, P., Diaferia, G., Locatelli, M., & Bellodi, L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00006 · Cited by 224
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena, S., Wang, D., Bystritsky, A., & Baxter, L. R. (1996) · PubMed · Cited by 154
Insight and treatment outcome in obsessive-compulsive disorder
Eisen, J. L., Rasmussen, S. A., Phillips, K. A., Price, L. H., Davidson, J. R. T., Lydiard, R. B., Ninan, P. T., & Pigott, T. A. (2001) · Comprehensive Psychiatry · doi:10.1053/comp.2001.27898 · Cited by 152
Insight and Resistance in Patients with Obsessive-Compulsive Disorder
Catapano, F., Sperandeo, R., Perris, F., Lanzaro, M., & Maj, M. (2001) · Psychopathology · doi:10.1159/000049282 · Cited by 124
Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania
Stein, D. J. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90462-9 · Cited by 123
Olanzapine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Ringold, A. L., & Elliott, M. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0709 · Cited by 111
Risperidone augmentation in refractory obsessive—compulsive disorder: an open-label study
Pfanner, C., Marazziti, D., Dell’Osso, L., Presta, S., Gemignani, A., Milanfranchi, A., & Cassano, G. B. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00007 · Cited by 83
Serotonin and Dopamine Antagonism in Obsessive-Compulsive Disorder: Effect of Atypical Antipsychotic Drugs
Ramasubbu, R., Ravindran, A. V., & Lapierre, Y. D. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-8360 · Cited by 74
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
Mohr, N., Vythilingum, B., Emsley, R. A., & Stein, D. J. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200201000-00006 · Cited by 69
Update on pharmacologic management of OCD: agents and augmentation.
McDougle, C. J. (1997) · PubMed · Cited by 65
Clinical predictors of drug response in obsessive-compulsive disorder
Denys, D. A. J. P., van Megen, H. J. G. M., & Westenberg, H. G. M. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80566-1 · Cited by 13
[Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
Hantouche, E. G., Bouhassira, M., & Lancrenon, S. (2001) · PubMed · Cited by 7
Risperidone augmentation in refractory obsessive compulsive disorder: An open-label study
Pfanner, C., Marazziti, D., Dell’Osso, L., Presta, S., Gemignani, A., Milanfranchi, A., & Cassano, G. B. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80450-2 · Cited by 6

Flagged first, then by citations

Sorted by citations

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“As adjunctive therapy for treatment-resistant OCD, risperidone was more effective than placebo (Level 1) [756-759] and as effective as olanzapine [760] and aripiprazole overall [755].”
Background
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Self-citation
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 884
Self-citation
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-analysis
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines
Pallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
Self-citation
Striatal Volume on Magnetic Resonance Imaging and Repetitive Behaviors in Autism
Hollander, E., Anagnostou, E. A., Chaplin, W. F., Esposito, K., Haznedar, M. M., LiCalzi, E. M., Wasserman, S., Soorya, L. V., & Buchsbaum, M. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.040 · Cited by 383
Self-citation
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Obsessive Compulsive Disorder
Hudak, R., & Gannon, J. M. (2022) · Current clinical practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1932 · Cited by 248
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Pittenger, C., Krystal, J. H., & Coric, V. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.006 · Cited by 225
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
CASALE, A. D., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 241
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
Evidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., & Gale, T. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004675 · Cited by 217
Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Obsessive-Compulsive Disorder
Goodman, W. K., Grice, D. E., Lapidus, K. A. B., & Coffey, B. J. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.06.004 · Cited by 221
Family Informants’ Perceptions of Insight in Compulsive Hoarding
Tolin, D. F., Fitch, K. E., Frost, R. O., & Steketee, G. S. (2008) · Cognitive Therapy and Research · doi:10.1007/s10608-008-9217-7 · Cited by 201
Impaired Prepulse Inhibition of Acoustic Startle in Obsessive-Compulsive Disorder
Hoenig, K., Hochrein, A., Quednow, B. B., Maier, W., & Wagner, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.040 · Cited by 190
Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study
Abraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis
Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0317-5 · Cited by 162
Obsessive–compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications
Poyurovsky, M., & Koran, L. M. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.09.004 · Cited by 139
Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv047 · Cited by 134
Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
Carey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133
Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: A meta-analysis of the randomized controlled trials
Skapinakis, P., Papatheodorou, T., & Mavreas, V. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.002 · Cited by 127
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.
Blier, P., & Szabo, S. T. (2005) · PubMed · Cited by 125
Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder
Koo, M.-S., Kim, E.-J., Roh, D., & Kim, C.-H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.148 · Cited by 125
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled Study
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122
Obsessive–compulsive disorder: a critical review of therapeutic perspectives
Schruers, K. R. J., Koning, K., Luermans, J., Haack, M., & Griez, E. J. L. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00502.x · Cited by 124
Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
Abudy, A., Juven‐Wetzler, A., & Zohar, J. (2011) · CNS Drugs · doi:10.2165/11587860-000000000-00000 · Cited by 118
Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study
Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105
Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch, M. H., & Storch, E. A. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.01.011 · Cited by 108
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Ipser, J., Carey, P. D., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473.pub2 · Cited by 102
Serotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Second-generation antipsychotics for obsessive compulsive disorder
Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008141.pub2 · Cited by 101
Duration of Untreated Illness as a Predictor of Treatment Response and Remission in Obsessive–Compulsive Disorder
Dell’Osso, B. M., Buoli, M., Hollander, E., & Altamura, A. C. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903418544 · Cited by 101
Self-citation
8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder
Maina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 92
A systematic review of evidence-based treatment strategies for obsessive- compulsive disorder resistant to first-line pharmacotherapy
Albert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Obsessive–compulsive disorder: A 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors
Catapano, F., Perris, F., Masella, M., Rossano, F., M, C., Magliano, L., & Maj, M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.04.010 · Cited by 82
A Review of the Treatment for Refractory Obsessive-Compulsive Disorder: From Medicine to Deep Brain Stimulation
Husted, D. S., & Shapira, N. A. (2004) · CNS Spectrums · doi:10.1017/s109285290000225x · Cited by 80
Obsessive-Compulsive Disorder in Tourette Syndrome
Goodman, W. K., Storch, E. A., Geffken, G. R., & Murphy, T. K. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210081201 · Cited by 76
Symptom Subtypes of Obsessive–Compulsive Disorder: Are they Relevant for Treatment?
Starčević, V., & Brakoulias, V. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802203442 · Cited by 85
Obsessive–Compulsive Disorder
Bokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
Augmentation strategies in obsessive–compulsive disorder
Arumugham, S. S., & Reddy, J. Y. C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.160 · Cited by 77
Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary study
Pessina, E., Albert, U., Bogetto, F., & Maina, G. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e9b91 · Cited by 71
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
Davidson, J., Zhang, W., Connor, K., Ji, J., Jobson, K. O., Lecrubier, Y., McFARLANE, A. C., Newport, D. J., Nutt, D., Osser, D. N., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096505 · Cited by 66
A review of antipsychotics in the treatment of obsessive compulsive disorder
Fineberg, N. A., Gale, T. M., & Sivakumaran, T. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056640 · Cited by 61
The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning
Brown, H. D., Amodeo, D. A., Sweeney, J. A., & Ragozzino, M. E. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111430749 · Cited by 56
Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review
Albert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats
Rogóż, Z., & Skuza, G. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70719-8 · Cited by 52
Diagnosis and treatment of obsessive-compulsive disorder and related disorders
Dell’Osso, B. M., Altamura, A. C., Mundo, E., Marazziti, D., & Hollander, E. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01167.x · Cited by 50
Self-citation
Latinos with obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials
Wetterneck, C. T., Little, T. E., Rinehart, K. L., Cervantes, M. E., Hyde, E., & Williams, M. T. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2011.12.001 · Cited by 51
Pharmacotherapies in the Management of Obsessive—Compulsive Disorder
Blier, P., Habib, R., & Flament, M. F. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100703 · Cited by 49
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Dhansay, Y., Jc, I., & Stein, D. J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473 · Cited by 47
Effectiveness of Long-Term Augmentation with Citalopram to Clomipramine in Treatment-Resistant OCD Patients
Marazziti, D., Golia, F., Consoli, G., Presta, S., Pfanner, C., Carlini, M., Mungai, F., & Dell’Osso, M. C. (2008) · CNS Spectrums · doi:10.1017/s1092852900014024 · Cited by 45
Pharmacological Augmentations of SRIs for Obsessive Compulsive Disorder
Leppink, E. W., & Grant, J. E. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch16 · Cited by 43
Management of Obsessive-Compulsive Disorder
Seibell, P. J., & Hollander, E. (2014) · F1000Prime Reports · doi:10.12703/p6-68 · Cited by 40
Self-citation
Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis
Zhou, D., Zhou, X., Li, Y., Zhang, K.-F., Lv, Z., Chen, X., Wan, L.-Y., Wang, W., Wang, G.-M., Li, D., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.009 · Cited by 43
An update on the pharmacological treatment of obsessive-compulsive disorder
Fontenelle, L. F., Nascimento, A. L., Mendlowicz, M. V., Shavitt, R. G., & Versiani, M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.563 · Cited by 41
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms
Egashira, N., Okuno, R., Matsushita, M., Abe, M., Mishima, K., Iwasaki, K., Nishimura, R., Oishi, R., & Fujiwara, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.100 · Cited by 42
Neurological considerations: Autism and Parkinson's disease
Hollander, E., Wang, A. T., Braun, A. R., & Marsh, L. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.07.014 · Cited by 44
Self-citation
Treatment-refractory obsessive compulsive disorder
Atmaca, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.12.004 · Cited by 38
Role of atypical opiates in OCD. Experimental approach through the study of 5-HT2A/C receptor-mediated behavior
Rojas-Corrales, M. O., Gibert‐Rahola, J., & Micó, J. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0619-5 · Cited by 38
Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders.
Keck, P. E., Strawn, J. R., & McElroy, S. L. (2006) · PubMed · Cited by 38
Different Views of Anxiety Disorders
Selek, S. (2011) · InTech eBooks · doi:10.5772/1022 · Cited by 39
Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis
Zhou, D., Zhou, X., Lv, Z., Chen, X., Wang, W., Wang, G.-M., Liu, C., Li, D.-Q., & Kuang, L. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.014 · Cited by 37
The Advantages of Choosing Antiobsessive Therapy According to Decision-Making Functioning
Cavedini, P., Bassi, T., Zorzi, C., & Bellodi, L. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000144889.51072.03 · Cited by 37
Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review
Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
Critical Review of the Use of Second-Generation Antipsychotics in Obsessive–Compulsive and Related Disorders
Kim, D., Ryba, N., Kalabalik, J., & Westrich, L. (2018) · Drugs in R&D · doi:10.1007/s40268-018-0246-8 · Cited by 37
Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges
Wolmarans, D. W., Scheepers, I. M., Stein, D. J., & Harvey, B. H. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0161-7 · Cited by 36
Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder
Foa, E. B., Simpson, H. B., Rosenfield, D., Liebowitz, M. R., Cahill, S. P., Huppert, J. D., Bender Jr, J., McLean, C. P., Maher, M. J., Campeas, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09044 · Cited by 34
Treatment strategies for obsessive-compulsive disorder
Marazziti, D., & Consoli, G. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903446948 · Cited by 37
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study
Prosser, J. M., Yard, S. S., Steele, A., Cohen, L. J., & GALYNKER, I. I. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-25 · Cited by 32
A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder
Brakoulias, V., & Stockings, E. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1540590 · Cited by 32
Antipsychotic augmentation in the treatment of obsessive-compulsive disorder
Jaisoorya, T. S., & Thamby, A. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_519_18 · Cited by 32
Effects of deep brain stimulation on prepulse inhibition in obsessive-compulsive disorder
Kohl, S., Gruendler, T. O. J., Huys, D., Sildatke, E., Dembek, T. A., Hellmich, M., Vorderwulbecke, M., Timmermann, L., Ahmari, S. E., Klosterkoetter, J., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.171 · Cited by 30
Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies
Stuchlı́k, A., Radostová, D., Brožka, H., Valeš, K., Nekovářová, T., Kopřivová, J., Svoboda, J., & Horáček, J. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00209 · Cited by 28
Treatment of obsessive-compulsive disorders (OCD) and obsessive-compulsive-related disorders (OCRD)
Krzyszkowiak, W., Kuleta-Krzyszkowiak, M., & Krzanowska, E. (2019) · Psychiatria Polska · doi:10.12740/pp/105130 · Cited by 29
Structure–activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity
Zagórska, A., Kołaczkowski, M., Bucki, A., Siwek, A., Kazek, G., Satała, G., Bojarski, A. J., Partyka, A., Wesołowska, A., & Pawłowski, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.046 · Cited by 28
Molecular mechanisms underlying synergistic effects of SSRI–antipsychotic augmentation in treatment of negative symptoms in schizophrenia
Chertkow, Y., Weinreb, O., Youdim, M. B. H., & Silver, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0255-4 · Cited by 26
Pharmacological treatment for obsessive–compulsive disorder
Fineberg, N. A., & Craig, K. J. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.04.001 · Cited by 26
How to grade categories of evidence
Bandelow, B., Zohar, J., Kasper, S. F., & Möller, H. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802456590 · Cited by 26
Clinical Pharmacology of Comorbid Obsessive–Compulsive Disorder in Tourette Syndrome
Neri, V., & Cardona, F. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00013-5 · Cited by 25
Creating more effective antidepressants: clues from the clinic
Rasmussen, K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.004 · Cited by 25
Catechol-O-Methyltransferase Gene Polymorphisms in Specific Obsessive–Compulsive Disorder Patients’ Subgroups
Melo-Felippe, F. B., Andrade, J. B. D. S., Giori, I. G., Vieira-Fonseca, T., Fontenelle, L. F., & Kohlrausch, F. B. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0697-0 · Cited by 28
Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial
Mowla, A., & Ghaedsharaf, M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001500 · Cited by 27
Augmenting serotonin reuptake inhibitors in obsessive–compulsive disorder: What moderates improvement?
Wheaton, M. G., Rosenfield, D., Foa, E. B., & Simpson, H. B. (2015) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000025 · Cited by 27
Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety?
Pies, R. W. (2009) · PubMed Central · Cited by 22
Resistência e refratariedade no transtorno obsessivo-compulsivo
Ferrão, Y. A., Diniz, J. B., Lopes, A. C., Shavitt, R. G., Greenberg, B. D., & Miguel, E. C. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006005000059 · Cited by 24
Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders
Ravindran, A. V., Bradbury, C. L., McKay, M. S., & da Silva, T. L. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1693 · Cited by 24
A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments
Lewin, A. B., Storch, E. A., Geffken, G. R., Goodman, W. K., & Murphy, T. K. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a810 · Cited by 22
Are Mentalizing Abilities and Insight Related to the Severity of Obsessive-Compulsive Disorder
İnanç, L., & Altıntaş, M. (2018) · Psychiatry Investigation · doi:10.30773/pi.2018.05.02.2 · Cited by 24
Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies
McLean, C. P., Zandberg, L. J., Meter, P. E. V., Carpenter, J. K., Simpson, H. B., & Foa, E. B. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09513 · Cited by 21
O conceito do insight em pacientes com transtorno obsessivo-compulsivo
Fontenelle, J. M., Santana, L., Lessa, L. D. R., da Victoria, M. S., Mendlowicz, M. V., & Fontenelle, L. F. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000100015 · Cited by 21
Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm
Miyamoto, J., Tsuji, M., Takeda, H., Ohzeki, M., Nawa, H., & Matsumiya, T. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.09.043 · Cited by 21
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 22
Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive–compulsive disorder: A network meta‐analysis
Maiti, R., Mishra, A., Srinivasan, A., & Mishra, B. R. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13568 · Cited by 22

Risperidone augmentation in refractory obsessive—compulsive disorder: an open-label study
Pfanner, C., Marazziti, D., Dell’Osso, L., Presta, S., Gemignani, A., Milanfranchi, A., & Cassano, G. B. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00007 · Cited by 83
Olanzapine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Ringold, A. L., & Elliott, M. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0709 · Cited by 111
[Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Árias, F., Soto, J. A., García-Cantalapiedra, M. J., Calvín, J. L. R., Morales, J., & Salgado, M. (2006) · PubMed · Cited by 9
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena, S., Wang, D., Bystritsky, A., & Baxter, L. R. (1996) · PubMed · Cited by 154
Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder
Hegde, A., Kalyani, B. G., Arumugham, S. S., Narayanaswamy, J. C., Math, S. B., & Reddy, Y. C. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000515 · Cited by 6

Authors: Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
University of Pisa (IT)
University of Florence (IT)
Corresponding author: Hollander, Eric
ORCID: Hollander, Eric
Sood, Erica
Pallanti, Stefano
Venue: The International Journal of Neuropsychopharmacology
Publisher: Oxford University Press (OUP)
Published: 2003-12
Volume: 6
Issue: 4
Pages: 397-401
ISSN: 1461-1457 (ISSN-L)
1469-5111
DOI: 10.1017/s1461145703003730
OpenAlex: W1966161934
Cited by: 197
References: 19
Citations by year: 2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 5 · 2015: 16 · 2014: 10 · 2013: 7 · 2012: 10
FWCI: 17.49
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The International Journal of Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Janssen Pharmaceuticals
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: risperidone, treatment-resistant OCD, augmentation therapy, serotonin reuptake inhibitors, antipsychotic augmentation, drug tolerability, treatment response, insight, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale
MeSH terms: Adult, Ambulatory Care, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Personality Inventory, Antipsychotic Agents, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks